Trial · NCT03566199

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199, Phase 1, Phase 2, Completed, Sabine Mueller, MD, PhD; results first posted 2022-02-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma. Trials, record NCT03566199. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03566199

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
NCT number: NCT03566199
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 7 participants, actual
Lead sponsor: Sabine Mueller, MD, PhD
Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: Panobinostat Nanoparticle Formulation MTX110, Convection-Enhanced Delivery (CED)
First posted: 2018-06-25
Last updated: 2022-02-25
Results first posted: 2022-02-25
Limitations and caveats: Phase 2 expansion cohort was not activated at behest of pharmaceutical supplier.

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Up to 12 Months	Adverse events and clinically significant laboratory abnormalities which meet Grade 3, 4, or 5 criteria according to Common Terminology Criteria for Adverse Events (CTCAE) classified by investigators and treating physicians as related to study treatment (probable, possible, and definite) will be summarized by maximum intensity/grade. Adverse events will be graded according to CTCAE version 4.0.
Secondary	Overall Survival Rate (OS) at 12 Months	Up to 12 Months	Overall survival is defined as the percentage of participants alive from time of diagnosis up to 12 months.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Up to 12 Months	While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study	proportion of participants	NUMBER
SECONDARY	Overall Survival Rate (OS) at 12 Months	Up to 12 Months	While individual participants were assigned to receive separate doses, participants are presented in one Arm/Group due to confidentiality concerns for this rare disease study	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Phase 1: Treatment (MTX110)	Muscle weakness right-sided (Grade 3)	0.142		proportion of participants
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Phase 1: Treatment (MTX110)	Stridor (Grade 3)	0.142		proportion of participants
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Phase 1: Treatment (MTX110)	Vagus nerve disorder (Grade 3)	0.142		proportion of participants
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Phase 1: Treatment (MTX110)	Gait disturbance (Grade 3)	0.142		proportion of participants
Proportion of Participants With Grade 3 or Higher, Treatment-related, Adverse Events	Phase 1: Treatment (MTX110)	Neutrophil count decreased (Grade 3)	0.142		proportion of participants
Overall Survival Rate (OS) at 12 Months	Phase 1: Treatment (MTX110)		85.7	95% Confidence Interval 63.3 to 100	percentage of participants

Source ClinicalTrials.gov

Participant flow24

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Phase 1: Starting Dose Level 1 (MTX110)	1
Overall Study	STARTED	Phase 1: Starting Dose Level 2 (MTX110)	0
Overall Study	STARTED	Phase 1: Starting Dose Level 3 (MTX110)	1
Overall Study	STARTED	Phase 1: Starting Dose Level 4 (MTX110)	0
Overall Study	STARTED	Phase 1: Starting Dose Level 5 (MTX110)	1
Overall Study	STARTED	Phase 1: Starting Dose Level 6 (MTX110)	0
Overall Study	STARTED	Phase 1: Starting Dose Level 7 (MTX110)	4
Overall Study	STARTED	Phase 2	0
Overall Study	COMPLETED	Phase 1: Starting Dose Level 1 (MTX110)	1
Overall Study	COMPLETED	Phase 1: Starting Dose Level 2 (MTX110)	0

1 to 10 of 24Source ClinicalTrials.gov

See all 24 participant flow

Adverse events73

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Fatigue	General disorders	Phase 1: Treatment (MTX110)	4	7	5
other	Gait disturbance	General disorders	Phase 1: Treatment (MTX110)	3	7	5
other	Pain	General disorders	Phase 1: Treatment (MTX110)	3	7	8
other	Irritability	General disorders	Phase 1: Treatment (MTX110)	1	7	1
other	Headache	Nervous system disorders	Phase 1: Treatment (MTX110)	5	7	8
other	Ataxia	Nervous system disorders	Phase 1: Treatment (MTX110)	4	7	17
other	Dizziness	Nervous system disorders	Phase 1: Treatment (MTX110)	4	7	5
other	Abducens nerve disorder	Nervous system disorders	Phase 1: Treatment (MTX110)	3	7	4
other	Dysarthria	Nervous system disorders	Phase 1: Treatment (MTX110)	2	7	7
other	Facial nerve disorder	Nervous system disorders	Phase 1: Treatment (MTX110)	2	7	2

1 to 10 of 73Source ClinicalTrials.gov

See all 73 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Phase 1: Treatment (MTX110)	7	7
Total, other adverse events	Phase 1: Treatment (MTX110)	7	7
Total, serious adverse events	Phase 1: Treatment (MTX110)	1	7

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03566199

GET https://conductscience.org/api/trials/v1/NCT03566199/flow?page=2

API reference For AI assistants